文献速递肾移植慢性肾脏病

肾移植损伤的基因组分析确定造血细胞激酶是肾纤维化的关键驱动因子

Genomic Analysis of Kidney Allograft Injury Identifies Hematopoietic Cell Kinase as a Key Driver of Renal Fibrosis.
PubMed 文献 · J Am Soc Nephrol · 2016-12-07

该研究通过人类肾活检标本的荟萃分析发现,在慢性肾移植损伤中Src家族酪氨酸激酶造血细胞激酶(Hck)上调。体外实验显示Hck过表达激活TGF-β/Smad3通路,而达沙替尼可抑制该通路及纤维化标志物。在小鼠单侧输尿管梗阻、狼疮肾炎及叶酸肾病模型中,达沙替尼减轻纤维化并改善肾功能。

要点

  • 慢性肾移植损伤活检标本中Hck表达上调
  • 达沙替尼在体外抑制TGF-β/Smad3通路及纤维化标志物
  • 动物模型中达沙替尼预处理减轻肾纤维化并改善肾功能

核心结论

  • Hck是肾纤维化的关键介质,达沙替尼可能被开发为抗纤维化药物。

研究设计与样本

  • 研究类型为人类肾活检标本的荟萃分析,整合了公开数据与本研究的慢性肾移植排斥基因组学研究,并进行了体外细胞实验和动物模型实验。

主要发现

  • 在慢性肾移植损伤的同种异体移植物中,Src家族酪氨酸激酶造血细胞激酶(Hck)表达上调。
  • 查询激酶抑制剂资源数据库发现,美国食品药品监督管理局批准的药物达沙替尼以高选择性强力结合Hck。
  • 体外实验中,Hck过表达激活TGF-β/Smad3通路,而HCK敲低则抑制该通路。
  • 达沙替尼处理肾小管细胞降低Col1a1表达,并减少成纤维细胞增殖和α-SMA表达。
  • 在小鼠单侧输尿管梗阻模型中,达沙替尼预处理显著减少促纤维化标志物上调、Smad3磷酸化及肾纤维化,而仅用溶媒预处理的肾脏则观察到这些变化;达沙替尼还改善肾功能、减少白蛋白尿,并在狼疮肾炎和叶酸肾病动物模型中抑制促纤维化标志物表达。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Renal fibrosis is the common pathway of progression for patients with CKD and chronic renal allograft injury (CAI), but the underlying mechanisms remain obscure. We performed a meta-analysis in human kidney biopsy specimens with CAI, incorporating data available publicly and from our Genomics of Chronic Renal Allograft Rejection study. We identified an Src family tyrosine kinase, hematopoietic cell kinase (Hck), as upregulated in allografts in CAI. Querying the Kinase Inhibitor Resource database revealed that dasatinib, a Food and Drug Administration-approved drug, potently binds Hck with high selectivity. In vitro, Hck overexpression activated the TGF-β/Smad3 pathway, whereas HCK knockdown inhibited it. Treatment of tubular cells with dasatinib reduced the expression of Col1a1 Dasatinib also reduced proliferation and α-SMA expression in fibroblasts. In a murine model with unilateral ureteric obstruction, pretreatment with dasatinib significantly reduced the upregulation of profibrotic markers, phosphorylation of Smad3, and renal fibrosis observed in kidneys pretreated with vehicle alone. Dasatinib treatment also improved renal function, reduced albuminuria, and inhibited expression of profibrotic markers in animal models with lupus nephritis and folic acid nephropathy. These data suggest that Hck is a key mediator of renal fibrosis and dasatinib could be developed as an antifibrotic drug.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Wei C, Li L, Menon MC, et al. Genomic Analysis of Kidney Allograft Injury Identifies Hematopoietic Cell Kinase as a Key Driver of Renal Fibrosis. J Am Soc Nephrol. 2016. PMID: 27927780. doi:10.1681/ASN.2016020238

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。